NaDeNo

Executive Summary

NaDeNo is a Norwegian biotechnology company founded in 2010 that is pioneering a novel drug delivery platform based on tissue-adhesive polymeric nanoparticles. The platform is designed for local administration, enabling high drug concentration at target sites while minimizing systemic toxicity. This approach addresses a critical need in oncology, where many chemotherapeutics cause severe off-target effects. The company’s lead candidate, PACAB-002, is a nanoformulation of cabazitaxel specifically targeting peritoneal micrometastases in ovarian cancer. Peritoneal metastases are a major cause of morbidity in ovarian cancer, and current treatments are limited by poor drug penetration and toxicity. NaDeNo’s technology aims to improve therapeutic index by adhering to the peritoneum and releasing the drug locally over an extended period. PACAB-002 is currently in Phase 1 clinical development, with initial dosing underway. The company has demonstrated preclinical proof-of-concept, showing significantly higher tumor drug concentrations and reduced systemic exposure compared to standard cabazitaxel. If successful, PACAB-002 could become a best-in-class therapy for ovarian cancer and potentially expand to other peritoneal malignancies. NaDeNo’s platform also holds promise for additional drug payloads and indications, though the immediate focus remains on advancing PACAB-002 through early clinical trials. The company is well-positioned in the drug delivery space, with a differentiated approach that could attract partnership interest from larger pharmaceutical companies.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim safety and pharmacokinetic data readout70% success
• H1 2027Announcement of strategic partnership or licensing deal for PACAB-00240% success